Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up
Berit Jordan(Martin Luther University Halle-Wittenberg), Karin Jordan(Heidelberg University), Fátima Cardoso(Breast Cancer Alliance), Patrick Jahn(Martin Luther University Halle-Wittenberg), Martin Taphoorn(Leiden University Medical Center), Matthias Preusser(Medical University of Vienna), Florian Scotté(Université Paris-Saclay), Émilie Le Rhun(University of Zurich), Anita Margulies(The Geneva Association), Guido Cavaletti(Bellvitge University Hospital), Hege Sagstuen Haugnes(University Hospital of North Norway)
Cited by 319
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k